Trials with Rechalange
Every colorectal cancer trial that includes this drug. Those looking for patients come first.
Showing 1–1 of 1
NCT07178717
This is an open-label, unicentre, single-arm Phase 2 study of encorafenib and cetuximab as rechallenge treatment in patients with BRAF V600E-mutant metastatic colorectal cancer after previous therapy with BRAF inhibitors-based combinations…